There is growing evidence that the host genetic make-up of an individual not only strongly influences risk of HIV-transmission and progression to AIDS but also plays a critical role in the development of specific AIDS defining illnesses such as HIV-associated dementia (HAD). In support of this hypothesis, we recently demonstrated that the GA/GA genotype for the monocyte chemoattractant protein 1 (MCP-1) gene is associated with a significantly increased risk of developing HAD. However, there are very few studies that have systematically determined the association between host genotype and development of HAD. In this collaborative study, we will test the following hypotheses.
Aim # 1 will test the overall hypothesis that expression of candidate genes that are known to promote or facilitate monocyte recruitment will alter risk of HAD. In this aim, we will investigate the genetic contribution of gene dosage of the chemokine MIP-1alphaP and variation in MMP-9 in HAD pathogenesis.
Aim #2 will test the hypothesis that expression of candidate cytokine or neurotoxin genes (e.g. TNFalpha) that are part of the MP-mediated inflammatory response to HIV infection in the brain alter the risk of HAD.
Aim #3 will test the hypothesis that neuronal susceptibility to MP-mediated inflammatory damage is linked to APOE genotypes. There are two significant strengths of this proposal: First, to address directly the importance of the host genetic of HAD, we will capitalize on the largest cohort of HIV-1 seropositive individuals (1,132 subjects) followed at a single U.S. medical center. Several unique epidemiological features, including the large number of Caucasians and African-Americans in this cohort, provide us the power to study the effects of genetic polymorphisms in HAD. Second, we will use a combination of epidemiologic study designs tailored to address each specific aim. For example, we will use the nested case-control study, the case-cohort study in addition to the traditional cohort study to dissect out the population level effects of various genotypes. The research is significant because (1) it will use the powerful approach of genetics to address the mechanisms underlying what arguably is the most common cause of dementia in the world in individuals less than the age of 40, namely HAD; (2) it has the potential for establishing a broadly applicable paradigm for approaches to dissect the genetic basis for other complex, multi-etiologic disorders in which the products of a multiplicity of genes interact with each other and with environmental factors. For example, given the similarities in the inflammatory processes associated with HAD, autoimmune diseases such as multiple sclerosis, and degenerative diseases such as AD and Parkinson's disease, our findings may provide evidence of common etiologic factors or genetic networks that play a role in the pathogenesis of this diverse group of diseases. Thus, this proposal seeks funds to support a collaborative study to explore the genetic mechanisms underlying HAD susceptibility by amalgamating the unique skills and resources of two different research teams, namely genetics (UTHSCSA) and epidemiology/virology/statistics (WHMC). This study will utilize pre-existing, anonymous, unlinked human specimens. IRB approval for genetic study of these specimens has been previously obtained under expedited review authorized by 45 CFR 46.110. We have submitted a request for addition of a new subtitle: """"""""Genetic epidemiology of HIV-associated dementia"""""""".

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
5R01MH069270-05
Application #
7322110
Study Section
Special Emphasis Panel (ZRG1-AARR-D (01))
Program Officer
Joseph, Jeymohan
Project Start
2004-02-09
Project End
2009-11-30
Budget Start
2007-12-01
Budget End
2009-11-30
Support Year
5
Fiscal Year
2008
Total Cost
$390,266
Indirect Cost
Name
University of Texas Health Science Center San Antonio
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Kalkonde, Y V; Shelton, R; Villarreal, M et al. (2011) The CC chemokine receptor 5 regulates olfactory and social recognition in mice. Neuroscience 197:153-61
Kulkarni, Hemant; Marconi, Vincent C; He, Weijing et al. (2009) The Duffy-null state is associated with a survival advantage in leukopenic HIV-infected persons of African ancestry. Blood 114:2783-92
Camargo, Jose F; Quinones, Marlon P; Mummidi, Srinivas et al. (2009) CCR5 expression levels influence NFAT translocation, IL-2 production, and subsequent signaling events during T lymphocyte activation. J Immunol 182:171-82
Kulkarni, Hemant; Agan, Brian K; Marconi, Vincent C et al. (2008) CCL3L1-CCR5 genotype improves the assessment of AIDS Risk in HIV-1-infected individuals. PLoS One 3:e3165
He, Weijing; Neil, Stuart; Kulkarni, Hemant et al. (2008) Duffy antigen receptor for chemokines mediates trans-infection of HIV-1 from red blood cells to target cells and affects HIV-AIDS susceptibility. Cell Host Microbe 4:52-62
Mamtani, M; Rovin, B; Brey, R et al. (2008) CCL3L1 gene-containing segmental duplications and polymorphisms in CCR5 affect risk of systemic lupus erythaematosus. Ann Rheum Dis 67:1076-83
Kulkarni, Hemant; Marconi, Vincent C; Agan, Brian K et al. (2008) Role of CCL3L1-CCR5 genotypes in the epidemic spread of HIV-1 and evaluation of vaccine efficacy. PLoS One 3:e3671
Catano, Gabriel; Kulkarni, Hemant; He, Weijing et al. (2008) HIV-1 disease-influencing effects associated with ZNRD1, HCP5 and HLA-C alleles are attributable mainly to either HLA-A10 or HLA-B*57 alleles. PLoS One 3:e3636
Mummidi, Srinivas; Adams, Lisa M; VanCompernolle, Scott E et al. (2007) Production of specific mRNA transcripts, usage of an alternate promoter, and octamer-binding transcription factors influence the surface expression levels of the HIV coreceptor CCR5 on primary T cells. J Immunol 178:5668-81
Kalkonde, Yogeshwar V; Morgan, William W; Sigala, Jose et al. (2007) Chemokines in the MPTP model of Parkinson's disease: absence of CCL2 and its receptor CCR2 does not protect against striatal neurodegeneration. Brain Res 1128:1-11

Showing the most recent 10 out of 11 publications